Dieter Marmé – författare

This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.​

This exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.​

Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosis, resulting in a net accumulation of tra- formed cells. Once a critical volume is achieved, lack of oxygen and nutrients limits further growth. To overcome this obstacle, the tumor cells initiate a program focused on the formation of new blood vessels within the host tissue. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases. Since its discovery more than 30 years ago by Dr. Judah Folkman, tumor angiog- esis has been proposed as an ideal target for novel tumor therapies. Today the first anti-angiogenic compounds are available for the treatment of patients but their s- cess in the clinic is rather limited when given as monotherapies. This is in contrast to many preclinical results which revealed a much higher efficacy of these therapeutics in appropriate animal models. The reasons for this discrepancy are manifold, one being the existence of more than one angiogenic signaling system capable of driving tumor angiogenesis. Therefore it is no surprise that the inhibition of just one system is not sufficient to block the formation of new blood vessels in patients.

Preface Tumor development and progression occur as a result of cumulative acquisition of genetic alterations affecting oncogenes and tumor suppressor genes. As a consequence of these alterations the arising tumor gains some fatal properties such as increased cell proliferation and decreased apoptosis, resulting in a net accumulation of tra- formed cells. Once a critical volume is achieved, lack of oxygen and nutrients limits further growth. To overcome this obstacle, the tumor cells initiate a program focused on the formation of new blood vessels within the host tissue. This process is termed tumor angiogenesis and contributes to the progression of most solid tumors and the formation of metastases. Since its discovery more than 30 years ago by Dr. Judah Folkman, tumor angiog- esis has been proposed as an ideal target for novel tumor therapies. Today the first anti-angiogenic compounds are available for the treatment of patients but their s- cess in the clinic is rather limited when given as monotherapies. This is in contrast to many preclinical results which revealed a much higher efficacy of these therapeutics in appropriate animal models. The reasons for this discrepancy are manifold, one being the existence of more than one angiogenic signaling system capable of driving tumor angiogenesis. Therefore it is no surprise that the inhibition of just one system is not sufficient to block the formation of new blood vessels in patients.

Die Pathogenese der Arteriosklerose ist immer noch weitgehend ungeklärt. In jüngster Zeit zeichnet sich jedoch ein wesentlicher Fortschritt im Verständnis der zugrundeliegenden kausalen Ereignisse ab. Das Entstehen arteriosklerotischer Läsionen beruht mit hoher Wahrscheinlichkeit auf einer Fehlsteuerung der interzellulären Kommunikation, die zum Verlust der Gefäßwandhomöostase führt. In einem komplexen Wechselspiel sind hieran hauptsächlich Wachstums- und Differenzierungsfaktoren beteiligt, deren biologische Funktion derzeit intensiv erforscht wird. Dieses Buch enthält eine Bestandsaufnahme über die zentrale Rolle dieser Wachstums- und Differenzierungsfaktoren beim Entstehen der Arteriosklerose. Es vermittelt Anstöße für grundlegende Forschungen auf diesem Gebiet, um zu neuen Therapiekonzepten im Kampf gegen die Arteriosklerose zu gelangen.

Die Pathogenese der Arteriosklerose ist immer noch weitgehend ungeklärt. In jüngster Zeit zeichnet sich jedoch ein wesentlicher Fortschritt im Verständnis der zugrundeliegenden kausalen Ereignisse ab. Das Entstehen arteriosklerotischer Läsionen beruht mit hoher Wahrscheinlichkeit auf einer Fehlsteuerung der interzellulären Kommunikation, die zum Verlust der Gefäßwandhomöostase führt. In einem komplexen Wechselspiel sind hieran hauptsächlich Wachstums- und Differenzierungsfaktoren beteiligt, deren biologische Funktion derzeit intensiv erforscht wird. Dieses Buch enthält eine Bestandsaufnahme über die zentrale Rolle dieser Wachstums- und Differenzierungsfaktoren beim Entstehen der Arteriosklerose. Es vermittelt Anstöße für grundlegende Forschungen auf diesem Gebiet, um zu neuen Therapiekonzepten im Kampf gegen die Arteriosklerose zu gelangen.